Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 393-410

  Goffredo, Veronica ^a   Paradiso, Angelo ^a   Ranieri, Girolamo ^a   Gadaleta, Cosmo Damiano ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

90Y ibritumomab tiuxetan; DOTATOC; Microspheres; Neuroendocrine tumours; Non Hodgkin's lymphoma; Radioembolization; Radionuclide therapy; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IBRITUMOMAB TIUXETAN; MICROSPHERE Y 90; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; PREDNISONE; RADIOACTIVE MICROSPHERE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SIR SPHERES; THERASPHERE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90; MONOCLONAL ANTIBODY; RECEPTOR; YTTRIUM;

ANTIBODY LABELING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PRACTICE; COLORECTAL CANCER; DOSIMETRY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LUNG TOXICITY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROCESS DEVELOPMENT; PROGRESSION FREE SURVIVAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTIFICIAL EMBOLISM; CLINICAL TRIAL (TOPIC); LIVER TUMOR; METABOLISM; NEOPLASM;

ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; NEUROENDOCRINE TUMORS; RADIOIMMUNOTHERAPY; RECEPTORS, PEPTIDE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 80655144474     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.012     Document Type: Review

References (177)

1. Saji H. Application of radiometallic compounds for medical diagnosis and therapy. Yakugaku Zasshi 2008, 128(3):323-332.
2. Gadaleta C., Mattioli V., Colucci G., et al. Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol 2004, 183(2):361-368.
3. Gadaleta C., Catino A., Ranieri G., et al. Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother 2004, 16(5):86-89.
4. Gadaleta C., Catino A., Mattioli V. Radiofrequency thermal ablation in the treatment of lung malignancies. In Vivo 2006, 20:765-768.
5. Gadaleta C.D., Catino A., Ranieri G., Armenise F., Console G., Mattioli V. Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall. J Exp Clin Cancer Res 2003, 22(4 Suppl.):203-206.
6. Gadaleta C., Catino A., Mattioli V. Stop-flow perfusion with mitomycin-C as locoregional approach in the treatment of large-unresectable liver metastases. In Vivo 2006, 20:769-772.
7. Gadaleta C., Catino A., Ranieri G., et al. Single-step therapy-feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009, 23(September-October (5)):813-820.
8. Catino A., Fazio V., Ranieri G., et al. Combined transarterial chemoembolization with irinotecan-loaded microspheres plus percutaneous RFA for the treatment of liver metastases: preliminary results. Presented at the cadiovascular and interventional radiological society of Europe annual meeting 2009.
9. Gadaleta C.D., Catino A., Rubini G., et al. Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: initial experience in twelve cases. Part I. J Clin Orthod 2009, 27(May (15S)):405s.
10. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31:1038-1046.
11. 90Y-DOTATOC in patients with neuroendocrine tumours. Anticancer Res 2006, 26(January-February (1B)):703-707.
12. Davies A.J. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007, 26(May (25)):3614-3628. [review].
13. Otte A., van de Wiele C., Dierckx A.R. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun 2009, 30:5-15.
14. Salem R., Thurston K.G. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 3. Comprehensive literature review and future direction. J Vasc Interv Radiol 2006, 17:1571-1593.
15. Vente M.A.D., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19:951-959.
16. Kocher D.C. Radioactive decay data tables 1981, National Technical Information Service, Springfield, [DOE/TIC-11026].
17. Kaplan I. Nuclear physics 1964, Addison-Wesley, New York.
18. Forrer F., Valkema R., Kwekkeboom D.J., de Jong M., Krenning E.P. Neuroendocrine tumour. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21(1):11-29. [review].
19. Wagner H.N., Wiseman G.A., Marcus C.S., et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002, 43:267-272.
20. Bushnell D. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumours. J Gastrointest Surg 2006, 10(3):335-336. [review].
21. Hubalewska-Dydejczyk A., Jurczak W., Sowa-Staszczak A., et al. New forms of radionuclide therapy with (90)Y in oncology. Nucl Med Rev Cent East Eur 2008, 11(1):5-11.
22. Zhang C.Y., Yokogoshi Y., Yoshimoto K., Fujinaka Y., Matsumoto K., Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 1995, 210(May (3)):805-815.
23. Reubi J.C., Laissue J.A. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 1995, 16(March (3)):110-115. [review].
24. Reubi J.C., Waser B., Liu Q., et al. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000, 85:3882-3891.
25. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27:273-282.
26. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPAd-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
27. Valkema R., De Jong M., Bakker W.H., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002, 32:110-122.
28. de Jong M., Breeman W.A., Bakker W.H., et al. Comparison of (111)In-labeled somatostatin analogues for tumour scintigraphy and radionuclide therapy. Cancer Res 1998, 58:437-441.
29. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24(4):389-427.
30. Moi M.K., Meares C.F., DeNardo S.J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N',N‴-tetraacetic acid and study of its yttrium(III) complex. J Am Chem Soc 1988, 110(18):6266-6267.
31. Deshpande S.V., DeNardo S.J., Kukis D.L., et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990, 31(April (4)):473-479.
32. Virgolini I., Britton K., Buscombe J., et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32:148-155.
33. Baum R.P., Soldner J., Schmucking M., Niesen A. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumours. Eur J Nucl Med 2004, 31(Suppl. 2):S238. [abstract].
34. Forrer F., Valkema R., Kwekkeboom D.J., de Jong M., Krenning E.P. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21(1):111-129.
35. 3] octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol 2005, 23:2754-2762.
36. Reubi J.C., Laissue J., Waser B., Horisberger U., Schaer J.C. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994, 733(September):122-137. [review].
37. Kwekkeboom D.J., Krenning E.P., Lebtahi R., et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumours: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009, 90(2):220-226. [Epub 2009 August 28].
38. National Council on Radiation Protection and Measurements Misadministration of radioactive material in medicine-scientific background 1991, National Council on Radiation Protection and Measurements, Bethesda, MD, p. 27.
39. Behr T.M., Sharkey R.M., Sgouros G., et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997, 80(12 Suppl.):2591-2610.
40. Rolleman E.J., Valkema R., de Jong M., et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003, 30:9-15.
41. Paganelli G., Zoboli S., Cremonesi M., et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001, 28(April (4)):426-434.
42. Otte A., Herrmann R., Heppeler A., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999, 26(11):1439-1447.
43. de Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumours: preclinical and clinical findings. Semin Nucl Med 2002, 32(2):133-140.
44. Chinol M., Bodei L., Cremonesi M., Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-d-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002, 32:141-147.
45. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1] octreotide and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20(8):716-731.
46. Bodei L., Cremonesi M., Zoboli S., et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003, 30:207-216.
47. Waldherr C., Pless M., Maecke H., et al. Tumour response and clinical benefit in neuroendocrine tumours after 7.4GBq 90Y-DOTATOC. J Nucl Med 2002, 43:610-616.
48. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
49. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992, 10:239-253.
50. Waldherr C., Pless M., Maecke H.R., Haldemann A., Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941-945.
51. Pless M., Waldherr C., Maecke H., Buitrago C., Herrmann R., Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer 2004, 45:365-371.
52. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumours. Semin Nucl Med 2006, 36:147-156.
53. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998, 351:417-418.
54. 90Y-DOTA-d-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002, 66:393-398.
55. Teunissen J.J., Kwekkeboom D.J., Krenning E.P. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 2006, 17:19-25.
56. Iten F., Muller B., Schindler C., et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer 2009, 115(May (10)):2052-2062.
57. Iten F., Müller B., Schindler C., et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007, 13(November (22 Pt 1)):6696-6702.
58. Dicembrino F., Varraso A., Mastroianno S., et al. Repeated neo-adjuvant nuclear medicine therapy with 90Y-DOTATOC allows successful surgical removal of a cephalopancreatic gastrinoma in a MEN-1 patient. J Endocr Investig 2007, 30(June (Suppl. 4)):120.
59. Nadler L.M., Stashenko P., Hardy R., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res 1980, 40:3147-3154.
60. Chapel H., Haeney M. Essentials of clinical immunology 1988, Blackwell Scientific Publications, Oxford.
61. Kwak L.W., Longo D.L. Monoclonal antibody therapy. The non-Hodgkin's lymphomas 1997, 703-705. Arnold, London. I.T. Magrath (Ed.).
62. Connors J.M. Radioimmunotherapy-hot new treatment for lymphoma. N Engl J Med 2005, 352:496-498.
63. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3793-3803.
64. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 2453-2463.
65. Wiseman G.A., Gordon L.I., Multani P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002, 99(12):4336-4342.
66. Maloney D.G. Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy. Semin Hematol 2000, 37:17-26.
67. Weigert O., Ilidge T., Hiddermann W., Dreyling M. Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006, 107:686-695.
68. Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol 2005, 32(February (1 Suppl. 1)):S36-S43.
69. Postema E.J., Boerman O.C., Oyen W.J., Raemaekers J.M., Corstens F.H. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 2001, 28(November (11)):1725-1735. [review].
70. Grillo-López A.J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002, 2(October (5)):485-493. [review].
71. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J Clin Oncol 1999, 17:3835-3849.
72. The Non-Hodgkin's Lymphoma Pathologic Classification Project National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982, 49:2112-2135.
73. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003, 44:465-474.
74. Hagenbeek A., Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005, 16(May (5)):786-792. [Epub 2005 March 31; Review].
75. Tennvall J., Fischer M., Bischof Delaloye A., et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007, 34(April (4)):616-622.
76. Morschhauser F., Illidge T., Huglo D., et al. Efficacy and safety of yttrium-90-ibritumomab-tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood 2007, 110:54.
77. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:1244-1253.
78. Ulaner G.A., Colletti P.M., Conti P.S. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy-initial experience. Radiology 2008, 246(March (3)):895-902. [Epub 2008 February 7].
79. Gordon L.I., Molina A., Witzig T., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004, 103:4429-4431.
80. Radford J.A., Ketterer N., Sebban C., et al. Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trial. Blood 2003, 102. (abstract 1484).
81. Coiffier B., Lepage E., Brie're J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346:235-242.
82. Shipley D.L., Greco F.A., Spigek D.R., et al. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2005, 23. [abstract 6577].
83. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20(August (15)):3262-3269.
84. DeMonaco N.A., Wu M., Osborn J., et al. Phase II trial of abbreviated chop-rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood 2005, 106(11). [abstract 2449].
85. Zinzani P.L., Tani M., Stefoni V., Alinari L., Marchi E., Fina M. A Phase II trial of fm (oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for previously untreated follicular lymphoma (FL) patients. Blood 2005, 106(11). [abstract 4763].
86. Zinzani P.L., Tani M., Stefoni V., Alinari L., Marchi E., Fina M. A phase II trial of chop chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (zevalin) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Blood 2005, 106(11). [abstract 4765].
87. Jurczak W., Giza A., Krochmalczyk D., et al. Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy (RIT). Blood 2005, 106(11). [abstract 2453].
88. Smith M.R., Chen H., Gordon L., et al. Phase II study of ituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol 2006, 24. [abstract 7503].
89. Hainsworth J.D., Spigel D.R., Markus T.M., et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009, 9(June (3)):223-228.
90. Van De Wiele C., Defreyne L., Peeters M., Lambert B. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q J Nucl Med Mol Imaging 2009, 53(June (3)):317-324. [review].
91. Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-977.
92. Kennedy A.S., Nutting C., Coldwell D., et al. Pathologic response and microdosimetry of yttrium-90 microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004, 60:1552-1563.
93. Yorke E.D., Jackson A., Fox R.A., et al. Can current models explain the lack of liver complication in Y-90 microsphere therapy?. Clin Cancer Res 1999, 5(Suppl. 10):3024s-3030s.
94. Ariel I.M. Radioactive isotopes for adjuvant cancer therapy. Arch Surg 1964, 89:244-249.
95. Ariel I. Intra-arterial injection of radioactive microspheres of ceramic in the treatment of malignant tumours. Indications and clinical results. Minerva Med 1965, 56:2030-2037.
96. Ariel I.M. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 1965, 162:267-278.
97. Ariel I.M., Flynn W., Pack G.T. Current possibilities of radioactive ceramic microspheres labeled with yttrium 90. Minerva Med 1967, 58:4496-4498.
98. Ariel I.M. Treatment of inoperable primary and metastatic cancer of the lung by internal irradiation. Surg Clin North Am 1967, 47:1483-1505.
99. Ariel I.M., Pack G.T. Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy. Cancer 1967, 20:793-804.
100. Blanchard R.J., Grotenhuis I., Lafave J.W., Frye C.W., Perry J.F. Treatment of experimental tumours: utilization of radioactive microspheres. Arch Surg 1964, 89:406-410.
101. Grady E.D. Intrahepatic arterial 90-yttrium resin spheres to treat liver cancer. Int J Nucl Med Biol 1978, 5:253-254.
102. Shepherd F.A., Rotstein L.E., Houle S., Yip T.C., Paul K., Sniderman K.W. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992, 70:2250-2254.
103. Ariel I.M., Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intra-arterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1978, 10:327-336.
104. Ariel I.M., Padula G. Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intra-arterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1982, 20:151-156.
105. Munty R., Nunez R., Szklaruk J., et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005, 25(Suppl. 1):S41-S55.
106. Andrews J.C., Walker S.C., Ackermann R.J., Cotton L.A., Ensminger W.D., Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994, 35:1637-1644.
107. Gray BN. Polymer based radionuclide containing particulate material. Patent application WO 02/34300 A1; 2002.
108. Avila-Rodriguez M.A., Selwyn R.G., Hampel J.A., et al. Positron-emitting resin microspheres as surrogates of 90Y SIR-Spheres: a radiolabeling and stability study. Nucl Med Biol 2007, 34:585-590.
109. Kalva S.P., Thabet A., Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics 2008, 28:101-117.
110. Food and Drug Administration Web site Guide for industry and FDA staff: humanitarian device exemption (HDE) regulation-questions and answers 2006, Available at: www.fda.gov/cdhr/ode/guidance//1381.html (accessed 30.11.2006).
111. Murthy R., Nunez R., Szklaruk J., et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices indications, technical considerations, and potential complications. Radiographics 2005, 25(Suppl. 1):S41-S55.
112. Sato K., Lewandowski R.J., Bui J.T., et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006, 29:522-529.
113. Kennedy A.S., Dezarn W.A., McNeillie P., et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31:271-279.
114. Stuart J.E., Tan B., Myerson R.J., et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol 2008, 19:1427-1433.
115. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIRSpheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12:1711-1720.
116. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65:412-425.
117. Sato K.T., Lewandowski R.J., Mulcahy M.F., et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 2008, 247:507-515.
118. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25:1099-1106.
119. Stubbs R.S., O'Brien I., Correia M.M. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006, 76:696-703.
120. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004, 127(Suppl.):S194-S205.
121. Lau W.Y., Ho S., Leung T.W., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998, 40:583-592.
122. Bangash A.K., Atassi B., Kaklamani V., et al. 90Y Radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007, 18:621-628.
123. Coldwell D.M., Kennedy A.S., Nutting C.W. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007, 69:800-804.
124. Jakobs T.F., Hoffmann R.T., Fischer T., et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008, 19:683-690.
125. King J., Quinn R., Glenn D.M., et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008, 113:921-929.
126. Rhee T.K., Lewandowski R.J., Liu D.M., et al. 90Y Radioembolization for metastatic neuroendocrine liver tumours: preliminary results from a multi-institutional experience. Ann Surg 2008, 247:1029-1035.
127. Murthy R., Kamat P., Nunez R., et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008, 19:145-151.
128. Ho S., Lau W.Y., Leung T.W.T., Chan M., Johnson P.J., Li A.K.C. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997, 24:293-298.
129. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic yttrium-90 microspheres. J Nucl Med 2000, 41:1673-1681.
130. Sarfaraz M., Kennedy A.S., Cao Z.J., et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumours. Med Phys 2003, 30:199-203.
131. Goin J.E. Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: dose-ranging study. World J Nucl Med 2003, 2:216-225.
132. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005, 16(February (2 Pt 1)):205-213.
133. Campbell A.M., Bailey I.H., Burton M.A. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001, 46:487-498.
134. Russell J.L., Carden J.L., Herron H.L., et al. Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocuriether Hypertherm Oncol 1988, 4:171-186.
135. Salem R., Thurston K.G., Carr B.I., et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002, 13:S223-S229.
136. Murthy R., Xiong H., Nunez R., et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005, 16:937-945.
137. Gulec S.A., Mesoloras G., Dezarn W.A., McNeillie P., Kennedy A.S. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 2007, 5(March):15.
138. Bult W., Vente M.A., Zonnenberg B.A., Van Het Schip A.D., Nijsen J.F. Microsphere radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging 2009, 53(June (3)):325-335. [review].
139. World Health Organization (WHO) WHO handbook for reporting results of cancer treatment 1979, WHO, Geneva, Switzerland, WHO Offset Publication No. 48.
140. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
141. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115(3):616-623.
142. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35(3):421-430.
143. Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008, 14(March (11)):1664-1669. [review].
144. Keppke A.L., Salem R., Reddy D., et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. Am J Roentgenol 2007, 188(3):768-775.
145. Liu M.D., Uaje M.B., Al-Ghazi M.S., et al. Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 2004, 70:947-953.
146. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumour response, and survival. J Vasc Interv Radiol 2005, 16:1627-1639.
147. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres: a risk stratification analysis. J Vasc Interv Radiol 2005, 16:195-203.
148. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005, 16:205-213.
149. Child C.G., Turcotte J.D. Surgery and portal hypertension. The liver and portal hypertension 1964, 1950. WB Saunders, Philadelphia. C.G. Child (Ed.).
150. Pugh R., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
151. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985, 56:918-928.
152. The Cancer of the Liver Italian Program (CLIP) Investigators A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998, 28:751-755.
153. Sangro B., Bilbao J.I., Boan J., et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 66(3):792-800.
154. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47:71-81.
155. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
156. Riaz A., Kulik L., Lewandowski R.J., et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009, 49(April (4)):1185-1193.
157. Carr B.I. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004, 10(2 Suppl. 1):S107-S110.
158. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138(1):52-64.
159. Lewandowski R.J., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9:1920-1928.
160. Wong C., Salem R., Raman S., et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F] FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002, 29:815-820.
161. Miller F.K., Keppke A.L., Reddy D., et al. Response of liver metastases after treatment with yttrium-90 microsphere: role of size, necrosis, and PET. Am J Roentgenol 2007, 188:776-783.
162. Mulcahy M.F., Lewandowski R.J., Ibrahim S., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009, 1849-1858.
163. Stubbs R., Cannan R., Mitchell A., et al. An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases. GI Cancer 1999, 3:135-143.
164. Lewandowski R., Thurston K., Goin J., et al. 90Y microsphere (Thera-Sphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005, 16:1641-1651.
165. Gray B., Van Hazel M., Buck M., et al. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer 2000, 3:249-257.
166. ® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12:1711-1720.
167. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004, 88:78-85.
168. Reubi J.C., Mäcke H.R., Krenning E.P. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005, 46(January (Suppl. 1)):67S-75S. [review].
169. Virgolini I., Traub T., Novotny C., et al. New trends in peptide receptor radioligands. Q J Nucl Med 2001, 45(June (2)):153-159. [review].
170. Lantry L.E., Cappelletti E., Maddalena M.E., et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006, 47(July (7)):1144-1152.
171. Hoffman T.J., Gali H., Smith C.J., et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
172. Schumacher T., Eichhorn K., Hofer S., et al. Diffusible brachytherapy (DBT) with radiolabelled substance P in high grade gliomas: first observations. Eur J Nucl Med 2001, 28:1040. [abstract].
173. Agazzi A., Rocca P., Laszlo D., et al. Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?. Eur J Haematol 2005, 74(May (5)):450-451.
174. Bodei L., Kassis A.I., Adelstein S.J., Mariani G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm 2003, 18(Dec 6):861-877. [review].
175. Bult W., Vente M.A., Zonnenberg B.A., Van Het Schip A.D., Nijsen JF Microsphere radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging 2009, 53(June (3)):325-335. [review].
176. Mumper R.J., Ryo U.Y., Jay M. Neutron-activated holmium-166-poly (l-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med 1991, 32:2139-2143.
177. Liepe K., Brogsitter C., Leonhard J., et al. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn J Clin Oncol 2007, 37:942-950.